28165762|t|Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial
28165762|a|This is a feasibility study evaluating the safety, tolerability, and potential anxiolytic efficacy of the α2 agonist guanfacine extended-release (GXR) in children and adolescents with generalized anxiety disorder (GAD), separation anxiety disorder (SAD), or social phobia / social anxiety disorder. Youth aged 6-17 years with a primary diagnosis of GAD, SAD, and/or social anxiety disorder were treated with flexibly dosed GXR (1-6 mg daily, n = 62) or placebo (n = 21) for 12 weeks. The primary aim of this study was to determine the safety and tolerability of GXR in youth with anxiety disorders, which involved the analysis of treatment - emergent adverse events (TEAEs), the emergence of suicidal ideation and behaviors, vital signs, and electrocardiographic / laboratory parameters. Exploratory efficacy measures included dimensional anxiety scales (Pediatric Anxiety Rating Scale [PARS] and Screen for Child Anxiety Related Emotional Disorders [SCARED]), as well as the Clinical Global Impression-Improvement (CGI-I) scale. As this was an exploratory study, no inferential statistical analyses were performed. GXR was safe and well tolerated. Treatment -related mean ± standard deviation changes in heart rate (GXR: 1.8 ± 12 beats per minute [bpm] decrease; placebo: 0.5 ± 11 bpm decrease), systolic blood pressure (GXR: 2.3 ± 11 mm Hg decrease; placebo: 1.7 ± 11 mm Hg decrease), or diastolic blood pressure (GXR: 1.3 ± 9 mm Hg decrease; placebo: 0.9 ± 7 mm Hg increase) were similar between treatment groups. TEAEs, including headache, somnolence / fatigue, abdominal pain, and dizziness, were consistent with the known safety profile of GXR. No differences were observed between treatment groups for PARS and SCARED scores, although at endpoint, a higher proportion of subjects receiving GXR versus placebo demonstrated CGI-I scores ≤2 (54.2% vs. 31.6%), as rated by the clinician investigator. GXR was well tolerated in pediatric subjects with GAD, SAD, and/or social anxiety disorder. ClinicalTrials.gov Identifier: NCT01470469.
28165762	0	16	Extended Release	T103	UMLS:C1707968
28165762	17	27	Guanfacine	T103	UMLS:C0079466
28165762	41	58	Anxiety Disorders	T038	UMLS:C0003469
28165762	62	67	Pilot	T062	UMLS:C0031928
28165762	69	79	Randomized	T062	UMLS:C0206034
28165762	81	99	Placebo-Controlled	T062	UMLS:C1706408
28165762	100	105	Trial	T062	UMLS:C0008976
28165762	116	133	feasibility study	T062	UMLS:C0015730
28165762	134	144	evaluating	T058	UMLS:C0220825
28165762	157	169	tolerability	T062	UMLS:C3274448
28165762	185	204	anxiolytic efficacy	T038	UMLS:C3179404
28165762	212	222	α2 agonist	T103	UMLS:C2267005
28165762	223	233	guanfacine	T103	UMLS:C0079466
28165762	234	250	extended-release	T103	UMLS:C1707968
28165762	252	255	GXR	T103	UMLS:C1707968
28165762	290	318	generalized anxiety disorder	T038	UMLS:C0270549
28165762	320	323	GAD	T038	UMLS:C0270549
28165762	326	353	separation anxiety disorder	T038	UMLS:C0003477
28165762	355	358	SAD	T038	UMLS:C0003477
28165762	364	377	social phobia	T038	UMLS:C0031572
28165762	442	451	diagnosis	T033	UMLS:C0011900
28165762	455	458	GAD	T038	UMLS:C0270549
28165762	460	463	SAD	T038	UMLS:C0003477
28165762	501	513	treated with	T058	UMLS:C0332293
28165762	529	532	GXR	T103	UMLS:C1707968
28165762	559	566	placebo	T103	UMLS:C1696465
28165762	614	619	study	T062	UMLS:C2603343
28165762	652	664	tolerability	T062	UMLS:C3274448
28165762	668	671	GXR	T103	UMLS:C1707968
28165762	686	703	anxiety disorders	T038	UMLS:C0003469
28165762	724	732	analysis	T062	UMLS:C0936012
28165762	736	745	treatment	T058	UMLS:C0087111
28165762	757	771	adverse events	T038	UMLS:C0877248
28165762	772	779	(TEAEs)	T038	UMLS:C0877248
28165762	798	815	suicidal ideation	T033	UMLS:C0424000
28165762	831	842	vital signs	T201	UMLS:C0518766
28165762	848	868	electrocardiographic	T058	UMLS:C0180580
28165762	871	881	laboratory	T092	UMLS:C0022877
28165762	945	959	anxiety scales	T170	UMLS:C4050613
28165762	1003	1055	Screen for Child Anxiety Related Emotional Disorders	T062	UMLS:C0681906
28165762	1020	1027	Anxiety	T033	UMLS:C0003467
28165762	1036	1055	Emotional Disorders	T038	UMLS:C0233459
28165762	1057	1063	SCARED	T062	UMLS:C0681906
28165762	1082	1120	Clinical Global Impression-Improvement	T170	UMLS:C3639708
28165762	1122	1127	CGI-I	T170	UMLS:C3639708
28165762	1151	1168	exploratory study	T062	UMLS:C1515369
28165762	1222	1225	GXR	T103	UMLS:C1707968
28165762	1244	1253	tolerated	T033	UMLS:C0013220
28165762	1255	1264	Treatment	T058	UMLS:C0087111
28165762	1311	1321	heart rate	T201	UMLS:C0018810
28165762	1323	1326	GXR	T103	UMLS:C1707968
28165762	1370	1377	placebo	T103	UMLS:C1696465
28165762	1403	1426	systolic blood pressure	T201	UMLS:C0871470
28165762	1428	1431	GXR	T103	UMLS:C1707968
28165762	1458	1465	placebo	T103	UMLS:C1696465
28165762	1496	1520	diastolic blood pressure	T201	UMLS:C0428883
28165762	1522	1525	GXR	T103	UMLS:C1707968
28165762	1551	1558	placebo	T103	UMLS:C1696465
28165762	1605	1614	treatment	T058	UMLS:C0087111
28165762	1615	1621	groups	T098	UMLS:C1257890
28165762	1623	1628	TEAEs	T038	UMLS:C0877248
28165762	1640	1648	headache	T033	UMLS:C0018681
28165762	1650	1660	somnolence	T038	UMLS:C2830004
28165762	1663	1670	fatigue	T033	UMLS:C0015672
28165762	1672	1686	abdominal pain	T033	UMLS:C0000737
28165762	1692	1701	dizziness	T033	UMLS:C0012833
28165762	1752	1755	GXR	T103	UMLS:C1707968
28165762	1794	1803	treatment	T058	UMLS:C0087111
28165762	1804	1810	groups	T098	UMLS:C1257890
28165762	1824	1830	SCARED	T062	UMLS:C0681906
28165762	1884	1892	subjects	T098	UMLS:C0080105
28165762	1903	1906	GXR	T103	UMLS:C1707968
28165762	1914	1921	placebo	T103	UMLS:C1696465
28165762	1935	1940	CGI-I	T170	UMLS:C3639708
28165762	1986	2008	clinician investigator	T097	UMLS:C0008961
28165762	2010	2013	GXR	T103	UMLS:C1707968
28165762	2023	2032	tolerated	T033	UMLS:C0013220
28165762	2036	2054	pediatric subjects	T098	UMLS:C0080105
28165762	2060	2063	GAD	T038	UMLS:C0270549
28165762	2065	2068	SAD	T038	UMLS:C0003477